Developer docs
API playgroundTry for free, no card

Search company profiles

SyntheticGestalt

Full company profile

uuid000276p

Namestring
SyntheticGestalt
Legal namestring
SyntheticGestalt KK
Company typeenum
Private
Founded yearint
2018
Descriptiontext

SyntheticGestalt KK is a Tokyo-based AI company founded in 2018 that develops molecule-specialized foundation AI models for drug discovery, enzyme discovery, and sustainable chemistry applications. The company's core technology is built around Geometric Deep Learning techniques applied to 1D, 2D, 3D, and 4D molecular structures (the last accounting for conformational changes), enabling accurate prediction of small molecule-protein interactions. Its flagship model, SG4D10B, is trained on 10 billion compound data points and has achieved world #1 rankings on the Therapeutics Data Commons standard evaluation framework for toxicity, permeability, and stability benchmarks. A compact version, SG4D100M, is distributed free of charge through Google Cloud Marketplace and AWS Marketplace to drive adoption among the broader research community.

The company operates two principal AI product systems—a Drug Discovery System (lead activity, drug-likeness, and novel compound generation across tens of billions of compound space) and an Enzyme Discovery System (applied to plastic-degrading enzymes, CO2-fixing enzymes, and pharmaceutical production enzymes)—complemented by joint development services that integrate clients' proprietary data with SyntheticGestalt's foundation models. Revenue is generated primarily through enterprise licensing and deployment agreements with pharmaceutical and industrial partners (e.g., Taiho Pharmaceutical, Shionogi, Kyowa Hakko Bio, Yokogawa Electric, Asahi Quality and Innovations), professional services for joint AI development, and a freemium distribution layer via cloud marketplaces. The company has raised approximately $17 million in total funding as of mid-2026, with a Series B in progress, and participates in multiple Japanese government-backed programs including GENIAC (Phases 2 and 3), LINK-J UNIKORN, and the J-StarX AI Medical Course for US market entry.

Short descriptiontext

SyntheticGestalt is a Tokyo-based AI company founded in 2018 that builds molecule-specialized foundation AI models (SG4D10B trained on 10 billion compounds) for pharmaceutical drug discovery, enzyme discovery, and sustainable chemistry, serving enterprise customers via licensing and joint development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMinato, Japan
HQ citystring
Minato
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular foundation models, AI drug discovery, enzyme discovery AI, generative molecular AI, green chemistry software
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Enterprise AI Licensing and Deployment
TypeSubscription Recurring
Description

B2B licensing of molecular foundation AI models (SG4D10B) to pharmaceutical companies through technical validation projects and long-term deployment agreements. Revenue generated from collaborative development, model access, and customization services with enterprise clients like Taiho Pharmaceutical.

syntheticgestalt.com
2Cloud Marketplace Distribution
TypeFreemium
Description

Free distribution of compact SG4D100M model on Google Cloud Marketplace and AWS Marketplace drives adoption and brand reach, potentially leading to enterprise upsell opportunities.

syntheticgestalt.com
3Joint Development Services
TypeProfessional Services
Description

Joint development of custom AI solutions powered by proprietary data for pharmaceutical, enzyme, and materials companies. Tailored approach transforms client data into competitive advantages through collaborative R&D partnerships.

syntheticgestalt.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1SG4D100M Compact Model - Free Tier
ModelFreemiumBilling cadenceOthers
Notes

Compact foundation model available at no cost on Google Cloud Marketplace and AWS Marketplace for research and evaluation purposes.

syntheticgestalt.com
2Enterprise Deployment - Custom Pricing
ModelSubscriptionBilling cadenceAnnual
Notes

Enterprise licensing and deployment of SG4D10B model with pharmaceutical partners through collaborative validation and deployment agreements. Pricing negotiated per client requirements.

syntheticgestalt.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

SyntheticGestalt develops and licenses molecule-specialized foundation AI models (SG4D10B and SG4D100M) that accelerate drug discovery and sustainable chemistry applications. The company's technology combines proprietary Geometric Deep Learning with 1D-4D molecular structural data to predict protein interactions, generate novel compounds, screen enzymes, and optimize leads for pharmaceutical, biomanufacturing, and chemical materials customers. Products are delivered through enterprise licensing agreements, joint development partnerships, and free cloud-marketplace distribution of the compact model.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Computational acceleration of 30,000 to 100,000 times for drug discovery and chemical development
+2 more records
Product overview1 text field

SyntheticGestalt offers a portfolio of molecule-specialized AI products centered on its foundation AI models (SG4D10B, SG4D100M) that form the core technology platform. The company's offerings span two main AI systems: the Drug Discovery System (for small molecule pharmaceutical research) and the Enzyme Discovery System (for biomanufacturing applications). These are complemented by collaborative services for joint AI development and joint substance discovery. The foundation models trained on billions of molecular data points serve as the underlying technology that powers all products and services, with the compact SG4D100M model providing accessible distribution through cloud marketplaces. The company also enables partner-specific solutions such as the Cysteinomix platform validation with Taiho Pharmaceutical.

Product and service7 records
1SG4D10B - Molecule-Specialized Foundation AI Model
CategoryFoundation AI Model
Description

World's largest molecule-specialized foundation AI model trained on 10 billion compound data points; achieves world #1 rankings in three critical drug discovery benchmarks (toxicity, permeability, stability) on the Therapeutics Data Commons standard evaluation framework. Deployed through enterprise licensing agreements with pharmaceutical partners including Taiho Pharmaceutical.

2SG4D100M - Compact Molecule-Specialized Foundation AI Model
CategoryFoundation AI Model
Description

Compact version of the molecule-specialized foundation AI model, available for free on Google Cloud Marketplace and AWS Marketplace to enable broader researcher and pharmaceutical-company access to the company's molecular AI technology for drug discovery and compound exploration.

3Drug Discovery System
CategoryDrug Discovery Platform
Description

AI-driven system that accelerates the drug discovery process by combining foundation AI models with predictive models of lead activity, drug-likeness, and novel compound generation. Selects optimal candidates from tens of billions of compound spaces for pharmaceutical customers.

4Enzyme Discovery System
CategoryBiomanufacturing AI Platform
Description

AI-powered enzyme discovery system that finds desired enzyme functions from large amounts of genetic sequence information. Applied to plastic-degrading enzymes, carbon dioxide-fixing enzymes, and pharmaceutical production enzymes for biomanufacturing customers.

5Joint Development of AI for Discovery of New Substances
CategoryAI Development Services
Description

Service offering that integrates SyntheticGestalt's foundation AI with clients' existing data and search infrastructure to create tailored AI solutions, transforming proprietary information into competitive advantages through collaborative R&D partnerships with pharmaceutical, enzyme, and materials companies.

6Joint Search for Novel Substances Using AI
CategoryAI Discovery Services
Description

Collaborative discovery service using proprietary AI technology to uncover valuable new compounds across pharmaceuticals and innovative materials, working alongside client R&D teams to enhance capabilities and drive scientific breakthroughs.

7iPS Cell Differentiation Target Discovery
CategoryResearch Services
Description

AI-powered research service that discovers new gene differentiation targets for liver regeneration from iPS cells by evaluating approximately 10 million gene combinations to significantly accelerate life sciences research.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-04
Description

Technical validation collaboration using SG4D10B molecular foundation AI model to enhance Taiho's Cysteinomix drug discovery platform. Aims to improve prediction accuracy of molecular profiles to increase success rate of discovering covalent drugs for historically undruggable targets. Taiho's Cysteinomix platform has track record of creating an agent approved in Japan, US, and Europe with multiple agents in clinical development.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-01
Description

Strategic partnership with Enamine to advance AI models for drug discovery. The collaboration enables SyntheticGestalt's AI to efficiently search Enamine's large libraries of tens of billions of compounds, suggesting candidate compounds for experiments with unprecedented speed and efficiency.

Strategic tierModerateTypeStrategic or Co-development PartnerAnnounced on2024-12-20
Description

Joint research on AI-powered PET bottle recycling technology called 'Bio-Recycling' to develop enzymatic decomposition methods for PET recycling at lower temperatures, discovering highly efficient PETase enzymes for scalable and sustainable PET recycling.

4Tokyo University of Science (Science Tokyo)
Strategic tierModerateTypeStrategic or Co-development PartnerAnnounced on2024-12-20
Description

Academic collaboration in joint research on next-generation AI-driven PET bottle recycling technology, contributing scientific expertise to the bio-recycling project.

syntheticgestalt.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Shionogi and Hokkaido University to identify new anti-coronavirus drug candidate compounds using SyntheticGestalt's AI drug discovery technology.

6Hokkaido University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership with Shionogi for anti-coronavirus drug candidate discovery using AI technology, combining university research capabilities with company AI expertise.

syntheticgestalt.com
7D. Western Therapeutics Institute (DWTI)
Strategic tierModerateTypeStrategic or Co-development Partner
Description

Collaboration to co-discover novel, multi-targeted kinase inhibitors for treatment of inflammation and central nervous system diseases, applying AI to DWTI's therapeutic focus areas.

syntheticgestalt.com
Strategic tierModerateTypeStrategic or Co-development Partner
Description

Enzyme screening partnership using company's enzyme discovery system to discover new enzymes applicable to pharmaceutical production with activity levels previously considered difficult to achieve, verified through wet experiments.

Strategic tierModerateTypeStrategic or Co-development Partner
Description

Research and development collaboration to create cell line identifier incorporating time information for cell evaluation technology, achieving solutions difficult with conventional methods.

10METI/NEDO (GENIAC Project)
Strategic tierCoreTypeOthers
Description

Selected for GENIAC (Generative AI Accelerator Challenge) - Japanese Ministry of Economy, Trade and Industry (METI) and NEDO project. Building chemical AI database 10x larger than current global standard with 100,000-200,000 entries. Achievement of computational acceleration of 30,000-100,000x for drug discovery.

syntheticgestalt.com
11LINK-J (UNIKORN Program)
Strategic tierModerateTypeOthers
Description

Selected for LINK-J's UNIKORN Phase 2 program, a startup support initiative focused on life science innovation, providing institutional backing and visibility within Japan's life sciences ecosystem.

syntheticgestalt.com
12METI/JETRO (J-StarX AI Medical Course)
Strategic tierCoreTypeOthers
Description

Selected for J-StarX AI Medical Course - competitive public-private initiative supporting Japanese healthtech startups' entry into US market. Maximum 12 companies receive specialized US healthcare ecosystem training, Mayo Clinic visits, and networking opportunities to establish US business foundation.

syntheticgestalt.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SyntheticGestalt

Drug Discovery Softwaresyntheticgestalt.com

SyntheticGestalt is a Tokyo-based AI company founded in 2018 that builds molecule-specialized foundation AI models (SG4D10B trained on 10 billion compounds) for pharmaceutical drug discovery, enzyme discovery, and sustainable chemistry, serving enterprise customers via licensing and joint development.

What SyntheticGestalt does

SyntheticGestalt KK is a Tokyo-based AI company founded in 2018 that develops molecule-specialized foundation AI models for drug discovery, enzyme discovery, and sustainable chemistry applications. The company's core technology is built around Geometric Deep Learning techniques applied to 1D, 2D, 3D, and 4D molecular structures (the last accounting for conformational changes), enabling accurate prediction of small molecule-protein interactions. Its flagship model, SG4D10B, is trained on 10 billion compound data points and has achieved world #1 rankings on the Therapeutics Data Commons standard evaluation framework for toxicity, permeability, and stability benchmarks. A compact version, SG4D100M, is distributed free of charge through Google Cloud Marketplace and AWS Marketplace to drive adoption among the broader research community.

The company operates two principal AI product systems—a Drug Discovery System (lead activity, drug-likeness, and novel compound generation across tens of billions of compound space) and an Enzyme Discovery System (applied to plastic-degrading enzymes, CO2-fixing enzymes, and pharmaceutical production enzymes)—complemented by joint development services that integrate clients' proprietary data with SyntheticGestalt's foundation models. Revenue is generated primarily through enterprise licensing and deployment agreements with pharmaceutical and industrial partners (e.g., Taiho Pharmaceutical, Shionogi, Kyowa Hakko Bio, Yokogawa Electric, Asahi Quality and Innovations), professional services for joint AI development, and a freemium distribution layer via cloud marketplaces. The company has raised approximately $17 million in total funding as of mid-2026, with a Series B in progress, and participates in multiple Japanese government-backed programs including GENIAC (Phases 2 and 3), LINK-J UNIKORN, and the J-StarX AI Medical Course for US market entry.

SyntheticGestalt firmographics

Firmographics
Name
SyntheticGestalt
Legal name
SyntheticGestalt KK
Website
https://syntheticgestalt.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
SyntheticGestalt is a Tokyo-based AI company founded in 2018 that builds molecule-specialized foundation AI models (SG4D10B trained on 10 billion compounds) for pharmaceutical drug discovery, enzyme discovery, and sustainable chemistry, serving enterprise customers via licensing and joint development.
Ownership category
akta.pro rank

SyntheticGestalt industry classification

Industry
Product category
Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Molecular foundation models
  • AI drug discovery
  • Enzyme discovery AI
  • Generative molecular AI
  • Green chemistry software

Where SyntheticGestalt is headquartered

Location

Headquarters

HQ city
Minato
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

SyntheticGestalt business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Enterprise AI Licensing and Deployment: B2B licensing of molecular foundation AI models (SG4D10B) to pharmaceutical companies through technical validation projects and long-term deployment agreements. Revenue generated from collaborative development, model access, and customization services with enterprise clients like Taiho Pharmaceutical.
  2. Cloud Marketplace Distribution: Free distribution of compact SG4D100M model on Google Cloud Marketplace and AWS Marketplace drives adoption and brand reach, potentially leading to enterprise upsell opportunities.
  3. Joint Development Services: Joint development of custom AI solutions powered by proprietary data for pharmaceutical, enzyme, and materials companies. Tailored approach transforms client data into competitive advantages through collaborative R&D partnerships.

Pricing tiers

ModelBillingPrice
FreemiumOthersSG4D100M Compact Model - Free Tier
SubscriptionAnnualEnterprise Deployment - Custom Pricing

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

SyntheticGestalt product offering

Product offering

Core offering

SyntheticGestalt develops and licenses molecule-specialized foundation AI models (SG4D10B and SG4D100M) that accelerate drug discovery and sustainable chemistry applications. The company's technology combines proprietary Geometric Deep Learning with 1D-4D molecular structural data to predict protein interactions, generate novel compounds, screen enzymes, and optimize leads for pharmaceutical, biomanufacturing, and chemical materials customers. Products are delivered through enterprise licensing agreements, joint development partnerships, and free cloud-marketplace distribution of the compact model.

Product overview

SyntheticGestalt offers a portfolio of molecule-specialized AI products centered on its foundation AI models (SG4D10B, SG4D100M) that form the core technology platform. The company's offerings span two main AI systems: the Drug Discovery System (for small molecule pharmaceutical research) and the Enzyme Discovery System (for biomanufacturing applications). These are complemented by collaborative services for joint AI development and joint substance discovery. The foundation models trained on billions of molecular data points serve as the underlying technology that powers all products and services, with the compact SG4D100M model providing accessible distribution through cloud marketplaces. The company also enables partner-specific solutions such as the Cysteinomix platform validation with Taiho Pharmaceutical.

Differentiator

Problem solved

Functional benefit

Products and services

  • SG4D10B - Molecule-Specialized Foundation AI Model World's largest molecule-specialized foundation AI model trained on 10 billion compound data points; achieves world #1 rankings in three critical drug discovery benchmarks (toxicity, permeability, stability) on the Therapeutics Data Commons standard evaluation framework. Deployed through enterprise licensing agreements with pharmaceutical partners including Taiho Pharmaceutical.
  • SG4D100M - Compact Molecule-Specialized Foundation AI Model Compact version of the molecule-specialized foundation AI model, available for free on Google Cloud Marketplace and AWS Marketplace to enable broader researcher and pharmaceutical-company access to the company's molecular AI technology for drug discovery and compound exploration.
  • Drug Discovery System AI-driven system that accelerates the drug discovery process by combining foundation AI models with predictive models of lead activity, drug-likeness, and novel compound generation. Selects optimal candidates from tens of billions of compound spaces for pharmaceutical customers.
  • Enzyme Discovery System AI-powered enzyme discovery system that finds desired enzyme functions from large amounts of genetic sequence information. Applied to plastic-degrading enzymes, carbon dioxide-fixing enzymes, and pharmaceutical production enzymes for biomanufacturing customers.
  • Joint Development of AI for Discovery of New Substances Service offering that integrates SyntheticGestalt's foundation AI with clients' existing data and search infrastructure to create tailored AI solutions, transforming proprietary information into competitive advantages through collaborative R&D partnerships with pharmaceutical, enzyme, and materials companies.
  • Joint Search for Novel Substances Using AI Collaborative discovery service using proprietary AI technology to uncover valuable new compounds across pharmaceuticals and innovative materials, working alongside client R&D teams to enhance capabilities and drive scientific breakthroughs.
  • iPS Cell Differentiation Target Discovery AI-powered research service that discovers new gene differentiation targets for liver regeneration from iPS cells by evaluating approximately 10 million gene combinations to significantly accelerate life sciences research.

Quantifiable outcome

  • Computational acceleration of 30,000 to 100,000 times for drug discovery and chemical development
  • +2 more outcomes

Companies that use SyntheticGestalt

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

SyntheticGestalt technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability6 records

Feature6 records

SyntheticGestalt partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and moderate.

  • Taiho PharmaceuticalcoreStrategic or Co-development Partner · 4 June 2025Technical validation collaboration using SG4D10B molecular foundation AI model to enhance Taiho's Cysteinomix drug discovery platform. Aims to improve prediction accuracy of molecular profiles to increase success rate of discovering covalent drugs for historically undruggable targets. Taiho's Cysteinomix platform has track record of creating an agent approved in Japan, US, and Europe with multiple agents in clinical development.
  • EnaminecoreTechnology or Integration · 1 January 2025Strategic partnership with Enamine to advance AI models for drug discovery. The collaboration enables SyntheticGestalt's AI to efficiently search Enamine's large libraries of tens of billions of compounds, suggesting candidate compounds for experiments with unprecedented speed and efficiency.
  • Asahi Quality and InnovationsmoderateStrategic or Co-development Partner · 20 December 2024Joint research on AI-powered PET bottle recycling technology called 'Bio-Recycling' to develop enzymatic decomposition methods for PET recycling at lower temperatures, discovering highly efficient PETase enzymes for scalable and sustainable PET recycling.
  • Tokyo University of Science (Science Tokyo)moderateStrategic or Co-development Partner · 20 December 2024Academic collaboration in joint research on next-generation AI-driven PET bottle recycling technology, contributing scientific expertise to the bio-recycling project.
  • Shionogi & Co., Ltd.coreStrategic or Co-development PartnerCollaboration with Shionogi and Hokkaido University to identify new anti-coronavirus drug candidate compounds using SyntheticGestalt's AI drug discovery technology.
  • Hokkaido UniversitycoreStrategic or Co-development PartnerAcademic partnership with Shionogi for anti-coronavirus drug candidate discovery using AI technology, combining university research capabilities with company AI expertise.
  • D. Western Therapeutics Institute (DWTI)moderateStrategic or Co-development PartnerCollaboration to co-discover novel, multi-targeted kinase inhibitors for treatment of inflammation and central nervous system diseases, applying AI to DWTI's therapeutic focus areas.
  • Kyowa Hakko Bio Co., Ltd.moderateStrategic or Co-development PartnerEnzyme screening partnership using company's enzyme discovery system to discover new enzymes applicable to pharmaceutical production with activity levels previously considered difficult to achieve, verified through wet experiments.
  • Yokogawa Electric CorporationmoderateStrategic or Co-development PartnerResearch and development collaboration to create cell line identifier incorporating time information for cell evaluation technology, achieving solutions difficult with conventional methods.
  • METI/NEDO (GENIAC Project)coreOthersSelected for GENIAC (Generative AI Accelerator Challenge) - Japanese Ministry of Economy, Trade and Industry (METI) and NEDO project. Building chemical AI database 10x larger than current global standard with 100,000-200,000 entries. Achievement of computational acceleration of 30,000-100,000x for drug discovery.
  • LINK-J (UNIKORN Program)moderateOthersSelected for LINK-J's UNIKORN Phase 2 program, a startup support initiative focused on life science innovation, providing institutional backing and visibility within Japan's life sciences ecosystem.
  • METI/JETRO (J-StarX AI Medical Course)coreOthersSelected for J-StarX AI Medical Course - competitive public-private initiative supporting Japanese healthtech startups' entry into US market. Maximum 12 companies receive specialized US healthcare ecosystem training, Mayo Clinic visits, and networking opportunities to establish US business foundation.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

SyntheticGestalt competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

SyntheticGestalt social profiles

Digital presence

SyntheticGestalt financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SyntheticGestalt leadership team

Management profile

Number of profiles

Profiles3 records

SyntheticGestalt funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SyntheticGestalt M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SyntheticGestalt

What does SyntheticGestalt do?

SyntheticGestalt develops and licenses molecule-specialized foundation AI models (SG4D10B and SG4D100M) that accelerate drug discovery and sustainable chemistry applications. The company's technology combines proprietary Geometric Deep Learning with 1D-4D molecular structural data to predict protein interactions, generate novel compounds, screen enzymes, and optimize leads for pharmaceutical, biomanufacturing, and chemical materials customers. Products are delivered through enterprise licensing agreements, joint development partnerships, and free cloud-marketplace distribution of the compact model.

Is SyntheticGestalt a public or private company?

SyntheticGestalt is a private company. It is classified as venture growth investor backed and is currently operating.

When was SyntheticGestalt founded?

SyntheticGestalt was founded in 2018. It employs 11 to 50 people.

Where is SyntheticGestalt based?

SyntheticGestalt is headquartered in Minato, Japan, in the Asia region.

How does SyntheticGestalt make money?

Three revenue lines are on record. Enterprise AI Licensing and Deployment is the primary driver. The others are cloud Marketplace Distribution and joint Development Services.

Does SyntheticGestalt have an API?

No public API is recorded for SyntheticGestalt.

What industry is SyntheticGestalt in?

SyntheticGestalt's product category is Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesEnamineとSyntheticGestalt、世界最大規模のAI創薬データ構築に向けた協業を発表SyntheticGestalt and Enamine announced a partnership to build the world's largest in vitro validated AI-driven chemical data ecosystem. The collaboration will analyze 100 protein targets and generate hundreds of thousands of data points, with the dataset planned for public release in 2027.EIN PresswireSyntheticGestalt and Enamine Build the World’s Largest Experimentally Validated AI-driven Chemical Data EcosystemSyntheticGestalt and Enamine announced a collaboration to build the world's largest experimentally validated AI-driven chemical data ecosystem. SyntheticGestalt will analyze 100 protein targets and prioritize compounds for synthesis, while Enamine provides its B-REAL platform. The dataset is expected to be released in 2027.EIN PresswireSyntheticGestalt Launches Molecular AI Models ZAO and KOYASyntheticGestalt launched ZAO, a molecular foundation model, and KOYA, a generative model, for drug discovery. ZAO ranked #1 on nine public benchmarks, and KOYA outperformed known ligands on eight of ten targets. Both are available via NVIDIA BioNeMo Agent Toolkit for enterprise use.PrtimesSyntheticGestalt、NVIDIA nvMolKitで4D分子基盤モデルを学習し、エージェント駆動の探索へSyntheticGestalt announced on June 23, 2026 that it is using NVIDIA nvMolKit to train its 4D molecular foundation model ZAO, which captures 3D molecular shapes. The model generated about 10 billion conformers, with nvMolKit achieving ~18,000 conformers per second on NVIDIA H200 GPUs. The company plans to develop AI agents using NVIDIA BioNeMo Agent Toolkit to automate molecular design.SyntheticgestaltSyntheticGestalt Tokyo Office Relocation NoticeSyntheticGestalt announced the relocation of its Tokyo office effective Sunday, March 8, 2025, with normal business operations resuming from Tuesday, March 10. The company, which develops AI technology specialized in molecular information and unveiled the world's largest molecule-specific foundation model at NVIDIA GTC, will move to 1101 H1O Hamamatsucho, 1-2-14 Shibadaimon, Minato-ku, Tokyo, 105-0012. Email addresses remain unchanged during the transition.SyntheticgestaltSyntheticGestalt presented GENIAC Phase 3 development achievements of molecular generative model at AI Leader's Meetup 2026 Spring!SyntheticGestalt announced that their CTO, Kotaro Kamiya, presented their Phase 3 development achievements of a molecular generative AI model at the AI Leader's Meetup 2026 Spring. The presentation highlighted advancements in compound design, model development utilizing Google Cloud, and collaboration with pharmaceutical companies. The company continues to develop molecular AI models for various sectors, including pharmaceuticals and chemicals.SyntheticgestaltAutomatic InventionSyntheticGestalt announced its achievements in molecular generative AI at an AI meetup in 2026, highlighting its selection for the GENIAC Phase 3 project aimed at creating the world's largest chemical AI data ecosystem. The project intends to significantly accelerate chemical and pharmaceutical research by utilizing large-scale foundation AI models trained on billions of data points.CB InsightsProducts, Competitors, Financials, Employees, Headquarters LocationsSyntheticGestalt, a Tokyo-based company specializing in machine learning for drug discovery, was founded in 2018 and has raised $11 million in funding. The company develops AI-driven products for pharmaceutical research, serving clients in the life sciences industry.Syntheticgestalt10 times larger than current global standard, set to accelerate pharmaceutical, agrochemical, and chemical industry development by up to 100,000-fold!SyntheticGestalt, a Tokyo-based molecule-specialized AI technology company founded in 2018, has been selected for GENIAC (Generative AI Accelerator Challenge), a project conducted by Japan's Ministry of Economy, Trade and Industry (METI) and NEDO. The initiative aims to build a chemical AI database 10 times larger than the current global standard with 100,000 to 200,000 entries, while achieving computational acceleration of 30,000 to 100,000 times for drug discovery and chemical development. Eight leading Japanese companies from pharmaceutical, agrochemical, and chemical sectors are collaborating on this project to strengthen Japan's international chemical industry competitiveness.SyntheticgestaltSyntheticGestalt to host a session "Advances in Foundation Models: Transforming Drug Discovery and Life Sciences" at CBI Annual Meeting 2025!SyntheticGestalt announced its participation in the CBI 2025 Annual Meeting, where it will host a session on advancements in foundation models and their impact on drug discovery and life sciences. The event, scheduled for October 28, 2025, in Tokyo, will feature presentations from various speakers on the latest AI case studies in the sector.